- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06151574
Beamion LUNG-2 : une étude visant à tester si le zongertinib (BI 1810631) aide les personnes atteintes d'un cancer du poumon non à petites cellules avancé avec des mutations HER2 par rapport au traitement standard
Beamion LUNG-2 : essai de phase III, ouvert, randomisé, contrôlé par actif, multicentrique évaluant le BI 1810631 administré par voie orale par rapport à la norme de soins comme traitement de première intention chez les patients atteints de tumeurs non squameuses non résécables, localement avancées ou métastatiques. Cancer du poumon à petites cellules hébergeant des mutations du domaine HER2 tyrosine kinase
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy.
Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein.
Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. Some visits may be conducted remotely later in the study if approved by the study doctor. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Augsburg, Allemagne, 86156
- Universitätsklinikum Augsburg
-
Berlin, Allemagne, 14089
- Gemeinschaftskrankenhaus Havelhöhe gGmbH
-
Cologne, Allemagne, 50937
- Universitätsklinikum Köln (AöR)
-
Dresden, Allemagne, 01307
- Universitätsklinikum Carl Gustav Carus Dresden
-
Giessen, Allemagne, 35392
- Justus-Liebig Universität Gießen
-
Heidelberg, Allemagne, 69126
- Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
-
Oldenburg, Allemagne, 26121
- Pius-Hospital, Oldenburg
-
Tübingen, Allemagne, 72076
- Universitätsklinikum Tübingen
-
-
-
-
-
CABA, Argentine, 1430
- Clinica Adventista Belgrano
-
Ciudad Autónoma de Bs As, Argentine, C1426ANZ
- Instituto Medico Especializado Alexander Fleming
-
Córdoba, Argentine, X5000
- Instituto Oncologico de Cordoba
-
La Rioja, Argentine, F5300COE
- Centro Oncologico Riojano Integral (CORI)
-
Rosario, Argentine, S2000DEJ
- Instituto Medico de la Fundacion Estudios Clinicos
-
-
-
-
New South Wales
-
Randwick, New South Wales, Australie, 2031
- Prince of Wales Hospital-Randwick-66496
-
St Leonards, New South Wales, Australie, 2065
- Royal North Shore Hospital-St Leonards-20807
-
-
Queensland
-
Woolloongabba, Queensland, Australie, 4102
- Princess Alexandra Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australie, 3084
- Austin Health
-
-
Western Australia
-
Subiaco, Western Australia, Australie, 6008
- St John of God Subiaco Hospital
-
-
-
-
-
Anderlecht, Belgique, 1070
- Brussels - HOSP Jules Bordet
-
Ghent, Belgique, 9000
- Universitair Ziekenhuis Gent
-
Leuven, Belgique, 3000
- UZ Leuven
-
-
-
-
-
Bento Gonçalves, Brésil, 95700-084
- Associacao Dr. Bartholomeu Tacchini
-
Londrina, Brésil, 86015-520
- Hospital do Câncer de Londrina
-
Porto Alegre, Brésil, 90610-000
- Hospital Sao Lucas da PUCRS
-
Rio de Janeiro, Brésil, 22250-905
- OncoClinicas Rio de Janeiro
-
Santo André, Brésil, 09060-650
- CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
-
São José do Rio Preto, Brésil, 15090-000
- Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
-
São Paulo, Brésil, 01246-000
- ICESP - Instituto do Cancer do Estado de Sao Paulo
-
-
-
-
-
Recoleta, Chili, 8420383
- Bradford Hill- Centro de Investigacion Clinica
-
-
-
-
-
Beijing, Chine, 100142
- Beijing Cancer Hospital
-
Beijing, Chine, 1000021
- Cancer Hospital of Chinese Academy of Medical Science
-
Chengdu, Chine, 610042
- West China Hospital, Sichuan University
-
Fuzhou, Chine, 350014
- Fujian Cancer Hospital
-
Guangzhou, Chine, 510080
- Guangdong Provincial People's Hospital
-
Hangzhou, Chine, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Chine, 310003
- The First Affiliated Hospital, Zhejiang University
-
Hangzhou, Chine, 310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
Harbin, Chine, 150081
- Harbin Medical University Cancer Hospital
-
Shanghai, Chine, 200032
- Fudan University Shanghai Cancer Center
-
Shanghai, Chine, 200032
- Zhongshan Hospital Affiliated to Fudan University
-
Taizhou, Chine, 317099
- Taizhou Hospital of Zhejiang Province
-
Wenzhou, Chine, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Chine, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xiamen, Chine, 361003
- First Affiliated Hospital of Xiamen University
-
Zhengzhou, Chine, 450008
- Henan Cancer Hospital
-
-
-
-
-
Cheongiu, Corée du Sud, 28644
- Chungbuk National University Hospital
-
Goyang, Corée du Sud, 10408
- National Cancer Center
-
Incheon, Corée du Sud, 21565
- Gachon University Gil Medical Center
-
Seoul, Corée du Sud, 05505
- Asan Medical Center
-
Seoul, Corée du Sud, 06351
- Samsung Medical Center
-
Seoul, Corée du Sud, 03181
- Kangbuk Samsung Hospital
-
Seoul, Corée du Sud, 03722
- Severance Hospital
-
Suwon, Corée du Sud, 16247
- The Catholic University of Korea, St.Vincent's Hospital
-
-
-
-
-
A Coruña, Espagne, 15006
- Complejo Hospitalario Universitario A Coruña
-
Alicante, Espagne, 03010
- Hospital General Universitario de Alicante
-
Barcelona, Espagne, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Espagne, 08026
- Hospital Santa Creu i Sant Pau
-
Barcelona, Espagne, 08908
- Hospital Duran i Reynals
-
Bilbao, Espagne, 48013
- Hospital de Basurto
-
Madrid, Espagne, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Madrid, Espagne, 28009
- Hospital General Universitario Gregorio Marañón
-
Madrid, Espagne, 28034
- Hospital Universitario Ramon Y Cajal
-
Málaga, Espagne, 29010
- Hospital Regional Universitario de Malaga
-
Seville, Espagne, 41013
- Hospital Virgen del Rocio
-
Valencia, Espagne, 46010
- Hospital Clinico Universitario de Valencia
-
-
-
-
-
Bron, France, 69677
- Hopital Louis Pradel
-
Lyon, France, 69373
- CTR Leon Berard
-
Marseille, France, 13015
- HOP Nord
-
Paris, France, 75248
- INS Curie
-
Paris, France, 75020
- HOP Tenon
-
Rennes, France, 35000
- HOP Pontchaillou
-
Strasbourg, France, 67091
- HOP Civil
-
Toulouse, France, 31059
- Hôpital Larrey - CHU de Toulouse
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Queen Mary Hospital
-
Hong Kong, Hong Kong, 999077
- Princess Margaret Hospital
-
Hong Kong, Hong Kong, 51727
- Queen Elizabeth Hospital-Hong Kong-51727
-
-
-
-
-
Haifa, Israël, 3109601
- Rambam Medical Center
-
Kfar Saba, Israël, 4428164
- Meir Medical Center
-
Petah Tikva, Israël, 49100
- Rabin Medical Center Beilinson
-
Tel Aviv, Israël, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italie, 70124
- Istituto Tumori Giovanni Paolo II
-
Candiolo (TO), Italie, 10060
- Istituto Di Candiolo
-
Catania, Italie, 95123
- Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
-
Naples, Italie, 80131
- Istituto Nazionale IRCCS Tumori Fondazione Pascale
-
Parma, Italie, 43100
- Azienda Ospedaliera Unversitaria di Parma
-
Roma, Italie, 00161
- AOU Policlinico Umberto I
-
Varese, Italie, 21100
- A. O. Ospedale Circolo Fond. Macchi
-
-
-
-
-
Aichi, Nagoya, Japon, 464-8681
- Aichi Cancer Center Hospital
-
Aomori, Hirosaki, Japon, 036-8563
- Hirosaki University Hospital
-
Chiba, Kashiwa, Japon, 277-8577
- National Cancer Center Hospital East
-
Ehime, Matsuyama, Japon, 791-0280
- Shikoku Cancer Center
-
Fukuoka, Fukuoka, Japon, 812-8582
- Kyushu University Hospital
-
Hokkaido, Hakodate, Japon, 040-8611
- Hakodate Goryoukaku Hospital
-
Hokkaido, Sapporo, Japon, 003-0804
- Hokkaido Cancer Center
-
Ishikawa, Kanazawa, Japon, 920-8641
- Kanazawa University Hospital
-
Kanagawa, Kawasaki, Japon, 216-8511
- St. Marianna University Hospital
-
Kanagawa, Yokohama, Japon, 241-8515
- Kanagawa Cancer Center
-
Kyoto, Kyoto, Japon, 602-8566
- University Hospital Kyoto Prefectural University of Medicine
-
Miyagi, Sendai, Japon, 980-8574
- Tohoku University Hospital
-
Okayama, Okayama, Japon, 700-8558
- Okayama University Hospital
-
Osaka, Osaka, Japon, 541-8567
- Osaka International Cancer Institute
-
Shizuoka, Sunto-gun, Japon, 411-8777
- Shizuoka Cancer Center
-
Tokyo, Bunkyo-ku, Japon, 113-8431
- Juntendo University Hospital
-
Tokyo, Bunkyo-ku, Japon, 113-8677
- Komagome Hospital
-
Tokyo, Chuo-ku, Japon, 104-0045
- National Cancer Center Hospital
-
Tokyo, Koto-ku, Japon, 135-8550
- Japanese Foundation for Cancer Research
-
Wakayama, Wakayama, Japon, 641-8510
- Wakayama Medical University Hospital
-
-
-
-
-
Krems, L'Autriche, 3500
- Krems University Hospital
-
Vienna, L'Autriche, 1210
- Clinic Floridsdorf
-
-
-
-
-
Lisbon, Le Portugal, 1350-352
- Hospital CUF Tejo
-
Lisbon, Le Portugal, 1769-001
- Centro Hospitalar Lisboa Norte Hospital Pulido Valente
-
Porto, Le Portugal, 4100-180
- Hospital CUF Porto
-
-
-
-
-
Mexico City, Mexique, 03100
- Health Pharma Professional Research S.A. de C.V.
-
México, Mexique, 14080
- Instituto Nacional de Cancerologia
-
México, Mexique, 06760
- Centro Oncologico Personalizado
-
Veracruz, Mexique, 91900
- FAICIC S de RL de C.V.
-
-
-
-
-
Drammen, Norvège, N-3004
- Vestre Viken HF, Drammen Sykehus
-
Oslo, Norvège, 0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Amsterdam, Pays-Bas, 1066 CX
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Amsterdam (METC AVL)
-
Maastricht, Pays-Bas, 6229 HX
- Maastricht University Medisch Centrum
-
-
-
-
-
Lodz, Pologne, 93-338
- Polish Mother's Memorial Hospital - Research Institute
-
Poznan, Pologne, 60-569
- Greater Poland Center of Pulmonology and Thoracic Surgery
-
Poznan, Pologne, 60693
- Med Polonia Sp. z o.o
-
Warsaw, Pologne, 02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Pan American Center for Oncology Trials, LLC
-
-
-
-
-
Edinburgh, Royaume-Uni, EH4 2XU
- Western General Hospital
-
Leicester, Royaume-Uni, LE1 5WW
- Leicester Royal Infirmary
-
London, Royaume-Uni, SE1 9RT
- Guy's Hospital
-
London, Royaume-Uni, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
Sutton, Royaume-Uni, SM2 5PT
- The Royal Marsden Hospital, Sutton
-
-
-
-
-
Singapore, Singapour, 168583
- National Cancer Centre Singapore
-
Singapore, Singapour, 119228
- National University Hospital-Singapore-22806
-
-
-
-
-
Gothenburg, Suède, 413 45
- Sahlgrenska Universitetsjukhuset
-
Stockholm, Suède, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
Kaohsiung City, Taïwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung, Taïwan, 404
- Chung Shan Medical University Hospital
-
Taipei, Taïwan, 100
- National Taiwan University Hospital
-
Taipei, Taïwan, 106
- National Taiwan University Cancer Center
-
Taoyuan, Taïwan, 330
- Chang Gung Memorial Hospital, Linkou
-
-
-
-
Alabama
-
Huntsville, Alabama, États-Unis, 35805
- Clearview Cancer Institute
-
-
Arizona
-
Bullhead City, Arizona, États-Unis, 86442
- Pioneer Research Center - Bullhead City
-
-
California
-
Beverly Hills, California, États-Unis, 90212
- Precision NextGen Oncology
-
Fresno, California, États-Unis, 93710
- ClinRé 001-022 (Premier Cancer Care and Infusion Center)
-
Glendale, California, États-Unis, 91203
- OPN Healthcare, Inc.
-
La Jolla, California, États-Unis, 92037
- Scripps Green Hospital
-
Los Angeles, California, États-Unis, 90067
- Valkyrie Clinical Trials
-
San Diego, California, États-Unis, 92123
- Sharp Memorial Hospital
-
-
Missouri
-
Bridgeton, Missouri, États-Unis, 63044
- St. Louis Cancer Care, LLP
-
Springfield, Missouri, États-Unis, 65807
- Oncology Hematology Associates
-
-
Nevada
-
Reno, Nevada, États-Unis, 89511
- Cancer Care Specialists
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- Northwell Health
-
The Bronx, New York, États-Unis, 10461
- Montefiore Medical Center
-
-
North Carolina
-
Wilson, North Carolina, États-Unis, 27893
- Regional Medical Oncology Center
-
-
Ohio
-
Canton, Ohio, États-Unis, 44718
- Gabrail Cancer Center
-
-
South Carolina
-
Rock Hill, South Carolina, États-Unis, 29732
- Carolina Blood and Cancer Care Associates, PA
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- SCRI Oncology Partners
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Virginia Cancer Specialists, PC
-
-
Washington
-
Edmonds, Washington, États-Unis, 98026
- Swedish Cancer Institute
-
Issaquah, Washington, États-Unis, 98029
- Swedish Cancer Institute
-
Seattle, Washington, États-Unis, 98104
- Swedish Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
- Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
- Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
- Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).
- Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
- An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.
- Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.
- Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment.
- Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information.
Further inclusion criteria apply.
Exclusion criteria:
-
Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;
- effectively treated non-melanoma skin cancers
- effectively treated carcinoma in situ of the cervix
- effectively treated ductal carcinoma in situ
- other effectively treated malignancy that is considered cured by local treatment
-
Tumors with targetable alterations with approved available therapy.
-
Lung-specific intercurrent clinically significant severe illness based on investigators assessment.
-
Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
-
Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.
-
Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.
-
History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.
-
Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block.
Further exclusion criteria apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental treatment arm
zongertinib only |
zongertinib
Autres noms:
|
|
Comparateur actif: Comparator arm
pembrolizumab plus platinum-pemetrexed chemotherapy |
pembrolizumab
Autres noms:
platinum-pemetrexed chemotherapy platinum-pemetrexed chemotherapy platinum-pemetrexed chemotherapy |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review
Délai: up to 4 years and 5 months
|
PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier. |
up to 4 years and 5 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changement entre le départ et la semaine 25 du score du domaine de la dyspnée NSCLC-SAQ
Délai: au départ, à la semaine 25
|
au départ, à la semaine 25
|
|
|
Changement entre le départ et la semaine 25 du score du domaine de la toux NSCLC-SAQ
Délai: au départ, à la semaine 25
|
au départ, à la semaine 25
|
|
|
Changement entre la ligne de base et la semaine 25 du score du domaine d'appétit NSCLC-SAQ
Délai: au départ, à la semaine 25
|
au départ, à la semaine 25
|
|
|
Changement entre le départ et la semaine 25 du score du domaine de fatigue NSCLC-SAQ
Délai: au départ, à la semaine 25
|
au départ, à la semaine 25
|
|
|
Survenance d'événements indésirables (EI) pendant la période de traitement, classés selon les critères de terminologie communs pour les événements indésirables (CTCAE) version 5.0
Délai: jusqu'à 53 mois
|
jusqu'à 53 mois
|
|
|
Apparition d'EI graves (EIG) pendant la période de traitement, classés selon CTCAE version 5.0
Délai: jusqu'à 53 mois
|
jusqu'à 53 mois
|
|
|
Key secondary endpoint: Overall Response (OR) according to RECIST 1.1 determined by blinded central independent review
Délai: up to 53 months
|
OR is defined as confirmed best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to RECIST 1.1 from date of randomization until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. |
up to 53 months
|
|
Key secondary endpoint: Change from baseline to Week 25 of Non-small cell lung cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score
Délai: at baseline, at week 25
|
The NSCLC-SAQ is a 7-item patient-reported outcome measure for use in adults to assess symptoms of advanced NSCLC. It contains five domains and accompanying items that were identified as symptoms of NSCLC: cough (1 item), pain (2), dyspnea (1), fatigue (2), and appetite (1). The (total) lowest score possible is 0, and the highest (total) score possible is 20. Higher scores indicate more severe symptoms. |
at baseline, at week 25
|
|
Key secondary endpoint: Overall Survival (OS)
Délai: up to 53 months
|
OS is defined as the time from randomization until death from any cause. |
up to 53 months
|
|
Duration of response (DoR), determined by blinded central independent review
Délai: up to 53 months
|
DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response. |
up to 53 months
|
|
PFS determined by blinded central independent review
Délai: up to 53 months
|
PFS is defined as the time from randomization until tumor progression or death from any cause, whichever occurs earlier. |
up to 53 months
|
|
Bi-compartmental PFS, determined by blinded central independent review
Délai: up to 53 months
|
Bi-compartmental PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier. |
up to 53 months
|
|
OR determined by blinded central independent review
Délai: up to 53 months
|
OR is defined as confirmed best overall response of CR or PR, from date of randomization until the earliest progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. |
up to 53 months
|
|
Change from baseline to Week 25 in the NSCLC-SAQ pain domain score
Délai: at baseline, at week 25
|
The individual NSCLC-SAQ items use a five-point verbal rating scale from "No <symptom> At All" to "Very severe <symptom>" or from "Never to Always," corresponding to an (item) score of 0 to 4. A higher score indicates more severe symptoms. |
at baseline, at week 25
|
|
Change from baseline to Week 25 in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) physical functioning domain score
Délai: at baseline, at week 25
|
The EORTC QLQ-C30 is a quality of life questionnaire. It ranges from 0 to 100, higher scores equal worse outcome. |
at baseline, at week 25
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Acides aminés, peptides et protéines
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Complexes de coordination
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Acides aminés, acides
- Acides aminés
- Acides aminés, dicarboxylique
- Composés en platine
- Pémétrexed
- Carboplatine
- Cisplatine
- pembrolizumab
Autres numéros d'identification d'étude
- 1479-0008
- 2023-504308-27-00 (Identificateur de registre: CTIS)
- U1111-1294-1407 (Autre identifiant: WHO International Clinical Trials Registry Platform (ICTRP))
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Délai de partage IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Critères d'accès au partage IPD
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .